In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Editas Medicine Inc’s stock clocked out at $2.09, down -5.86% from its previous closing price of $2.22. In other words, the price has decreased by -$5.86 from its previous closing price. On the day, 1.92 million shares were traded. EDIT stock price reached its highest trading level at $2.22 during the session, while it also had its lowest trading level at $2.055.
Ratios:
To gain a deeper understanding of EDIT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 5.85 whereas as Long-Term Debt/Eq ratio is at 5.03.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’25 when Burkly Linda sold 713 shares for $2.15 per share. The transaction valued at 1,535 led to the insider holds 68,777 shares of the business.
O’Neill Gilmore Neil sold 5,603 shares of EDIT for $12,064 on Dec 03 ’25. The CEO now owns 269,087 shares after completing the transaction at $2.15 per share. On Dec 03 ’25, another insider, Parison Amy, who serves as the SVP, Chief Financial Officer of the company, sold 461 shares for $2.15 each. As a result, the insider received 993 and left with 15,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 204022976 and an Enterprise Value of 58027000. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.40 while its Price-to-Book (P/B) ratio in mrq is 14.49. Its current Enterprise Value per Revenue stands at 1.251 whereas that against EBITDA is -0.518.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.15, which has changed by 0.8196721 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.54, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -11.66%, while the 200-Day Moving Average is calculated to be -13.98%.
Shares Statistics:
It appears that EDIT traded 2.05M shares on average per day over the past three months and 1952050 shares per day over the past ten days. A total of 97.62M shares are outstanding, with a floating share count of 97.12M. Insiders hold about 0.51% of the company’s shares, while institutions hold 45.48% stake in the company. Shares short for EDIT as of 1767139200 were 11320572 with a Short Ratio of 5.53, compared to 1764288000 on 10568381. Therefore, it implies a Short% of Shares Outstanding of 11320572 and a Short% of Float of 11.62.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Editas Medicine Inc (EDIT) in the stock market.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.63 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.14, with 8.0 analysts recommending between -$0.62 and -$1.41.
Revenue Estimates
In. The current quarter, 12 analysts expect revenue to total $8.45M. It ranges from a high estimate of $40.5M to a low estimate of $500k. As of. The current estimate, Editas Medicine Inc’s year-ago sales were $30.6MFor the next quarter, 12 analysts are estimating revenue of $1.38M. There is a high estimate of $3.77M for the next quarter, whereas the lowest estimate is $500k.
A total of 13 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $56.28M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $23.63M. In the same quarter a year ago, actual revenue was $32.31MBased on 13 analysts’ estimates, the company’s revenue will be $16.65M in the next fiscal year. The high estimate is $41M and the low estimate is $2M.
